Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.

Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT.

Cancer Discov. 2020 Jan 23. doi: 10.1158/2159-8290.CD-19-0710. [Epub ahead of print]

PMID:
31974170
2.

Arbuscular mycorrhizal fungi in roots and soil respond differently to biotic and abiotic factors in the Serengeti.

Stevens BM, Propster JR, Öpik M, Wilson GWT, Alloway SL, Mayemba E, Johnson NC.

Mycorrhiza. 2020 Jan;30(1):79-95. doi: 10.1007/s00572-020-00931-5. Epub 2020 Jan 22.

PMID:
31970495
3.

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.

Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA.

Blood Adv. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243.

4.

CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E.

Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25.

5.

Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis.

Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Myers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM.

Haematologica. 2020 Mar;105(3):585-597. doi: 10.3324/haematol.2018.197210. Epub 2019 May 17.

6.

Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.

Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, Jordan CT.

Blood. 2019 Jul 25;134(4):389-394. doi: 10.1182/blood.2019898114. Epub 2019 May 17.

PMID:
31101624
7.

The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells.

Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, Pollyea DA, Becker MW, Jordan CT.

Cell Rep. 2019 Apr 2;27(1):238-254.e6. doi: 10.1016/j.celrep.2019.03.009.

8.

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT.

Cancer Cell. 2019 Feb 11;35(2):333-335. doi: 10.1016/j.ccell.2019.01.013. No abstract available.

9.

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT.

Cancer Cell. 2018 Nov 12;34(5):724-740.e4. doi: 10.1016/j.ccell.2018.10.005. Erratum in: Cancer Cell. 2019 Feb 11;35(2):333-335.

10.

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT.

Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12.

11.

Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells.

Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, Colgan SP, Jordan CT.

Cancer Cell. 2018 Oct 8;34(4):659-673.e6. doi: 10.1016/j.ccell.2018.08.016. Epub 2018 Sep 27.

12.

Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.

Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT.

Nat Commun. 2018 Sep 12;9(1):3694. doi: 10.1038/s41467-018-05984-x.

13.

AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells.

Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT.

Cell Stem Cell. 2018 Jul 5;23(1):86-100.e6. doi: 10.1016/j.stem.2018.05.021. Epub 2018 Jun 14.

14.

Acute dietary nitrate supplementation does not attenuate oxidative stress or the hemodynamic response during submaximal exercise in hypobaric hypoxia.

Carriker CR, Rombach P, Stevens BM, Vaughan RA, Gibson AL.

Appl Physiol Nutr Metab. 2018 Dec;43(12):1268-1274. doi: 10.1139/apnm-2017-0813. Epub 2018 May 18.

PMID:
29775547
15.

Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.

Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT.

J Biol Chem. 2016 Nov 25;291(48):25280. No abstract available.

16.

Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.

Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT.

J Biol Chem. 2016 Oct 14;291(42):21984-22000. Epub 2016 Aug 29. Erratum in: J Biol Chem. 2016 Nov 25;291(48):25280.

17.

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.

Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW.

Blood. 2016 Sep 29;128(13):1671-8. doi: 10.1182/blood-2016-02-695312. Epub 2016 Jul 15.

18.

Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J.

Clin Cancer Res. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29.

19.

Redox biology in normal cells and cancer: restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.

Noble M, Mayer-Pröschel M, Li Z, Dong T, Cui W, Pröschel C, Ambeskovic I, Dietrich J, Han R, Yang YM, Folts C, Stripay J, Chen HY, Stevens BM.

Free Radic Biol Med. 2015 Feb;79:300-23. doi: 10.1016/j.freeradbiomed.2014.10.860. Epub 2014 Dec 4. Review.

PMID:
25481740
20.

Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.

Stevens BM, Folts CJ, Cui W, Bardin AL, Walter K, Carson-Walter E, Vescovi A, Noble M.

Stem Cells. 2014 May;32(5):1124-35. doi: 10.1002/stem.1644.

21.

Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells.

Chen HY, Yang YM, Stevens BM, Noble M.

EMBO Mol Med. 2013 May;5(5):723-36. doi: 10.1002/emmm.201202140. Epub 2013 Apr 22.

22.

The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.

Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT.

Blood. 2008 Nov 15;112(10):4184-92. doi: 10.1182/blood-2008-02-142190. Epub 2008 Aug 28.

23.

Bacterial community structure of acid-impacted lakes: what controls diversity?

Percent SF, Frischer ME, Vescio PA, Duffy EB, Milano V, McLellan M, Stevens BM, Boylen CW, Nierzwicki-Bauer SA.

Appl Environ Microbiol. 2008 Mar;74(6):1856-68. doi: 10.1128/AEM.01719-07. Epub 2008 Feb 1.

24.

"Rapidly labelled" ribonucleic acid in rat-liver "calcium supernatant" fractions.

REID E, STEVENS BM.

Biochim Biophys Acta. 1961 Apr 29;49:215-8. No abstract available.

PMID:
13740482
25.

Ribonucleic acids in liver cytoplasm.

REID E, STEVENS BM.

Nature. 1958 Aug 16;182(4633):441-4. No abstract available.

PMID:
13577871
26.
27.
29.

Hormonal influences on the incorporation of injected precursors into the protein and ribonucleic acid of liver cytoplasm.

BURNOP VC, O'NEAL MA, REID E, STEVENS BM.

Biochem J. 1956 Sep;64(1):33-8. No abstract available.

30.

Functions of ribonucleic acid in liver cytoplasm.

REID E, STEVENS BM.

Biochim Biophys Acta. 1956 Mar;19(3):554-5. No abstract available.

PMID:
13315321

Supplemental Content

Loading ...
Support Center